Abbreviations
2-AG, 2-arachidonoyl-glycerol; 5-HT1A, serotoninergic receptors of the 5-HT1A type; AEA, anandamide; BCP, β-caryophyllene; CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; CBC, cannabichromene; CBD, cannabidiol; CBDA, cannabidiolic acid; CBDV, cannabidivarin; CBG, canabigerol; CNS, Central nervous system; D; DAGLα, diacylglycerol lipase α; DAGL, sn-1-diacylglycerol lipase; DAGLβ, diacylglycerol lipase β; EAE, Experimental autoimmune encephalomyelitis; ERK, protein extracellular signal-regulated kinase; ES, endocannabinoid system; FAAH, fatty acid amide hydrolase; FDA, Food and Drug Administration; FoxP3, Forkhead box P3; GABAA, γ-Aminobutyric acid type A;  GPCRs, orphan G protein-coupled receptors; GPR118; G protein-coupled receptor 118; GPR119; G protein-coupled receptor 119; GPR18; G protein-coupled receptor 18; GPR55, G protein-coupled receptor 55; IL-10, Interleukin-10; IL-17, Interleukin-17; IL-1β, Interleukin 1 beta; IL-4, Interleukin-4; IL-6, Interleukin-6; INF-γ, Interferon gamma; MAGL, monoacylglycerol lipase; miRNA, MicroRNA; MS, Multiple sclerosis; NAPE-PLD, N-acyl-phosphatidyl ethanolamine-specific phospholipase; OEA, N-oleoylethanolamine; PEA, N-palmitoylethanolamine; PPARα, peroxisome proliferator-actived receptor α; PPARγ, peroxisome proliferator-actived receptor γ; STAT5b, signal transducer and activator of transcription 5B; TBX21; T-box transcription factor 21; TGF-β, Transforming growth factor beta; THC, Δ9 -tetrahidrocanabinol;  THCA, ∆9-tetrahydrocannabinolic acid; THCV, ∆9- tetrahydrocannabivarin; TNF-α, Tumor necrosis factor alpha; TRPM8, transient receptor potential cation channel subfamily M (melastatin) member 8; TRPV1, transient receptor potential vanilloid 1.